Rapid RV/LV vs LINQ II Insertable Cardiac Monitor

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Rapid RV/LV

by RapidAI (formerly iSchemaView)

LINQ II Insertable Cardiac Monitor

by Medtronic

AI Verdict

Tool A specializes in AI-powered rapid assessment of pulmonary embolism severity through CTPA scan analysis, providing immediate diagnostic support for acute conditions. Conversely, Tool B is an insertable cardiac monitor utilizing AI for long-term, continuous heart rhythm monitoring to diagnose arrhythmias. While both fall under cardiology AI, their distinct applications in acute imaging interpretation versus chronic rhythm monitoring make them adjacent rather than direct competitors.

Choose Rapid RV/LV if…

Choose Rapid RV/LV if your clinical setting requires immediate, objective assessment of pulmonary embolism (PE) severity from CTPA scans. This AI tool is ideal for emergency departments or critical care units where rapid, automated measurement of RV/LV ratios can inform urgent treatment decisions and streamline patient triage for suspected PE cases. It helps reduce inter-rater variability and provides critical insights within minutes of a scan.

View Rapid RV/LV →

Choose LINQ II Insertable Cardiac Monitor if…

Choose the Medtronic LINQ II if you need long-term, continuous heart rhythm monitoring to diagnose infrequent or paroxysmal arrhythmias over an extended period. This insertable cardiac monitor is best suited for patients requiring up to 4.5 years of monitoring, offering AI-powered accuracy and the convenience of remote programming and data transmission via a mobile app. It's particularly useful when other short-term monitoring methods have failed to capture symptomatic or asymptomatic arrhythmias.

View LINQ II Insertable Cardiac Monitor →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Rapid RV/LV	LINQ II Insertable Cardiac Monitor
Pricing	Contact vendor for pricing information.	Unknown
Deployment	On-premises (dedicated server or virtual machine) or hybrid (on-premises/cloud with secure link to cloud), connecting to hospital LAN/firewall.	Subcutaneous implant with remote monitoring via mobile app or home communicator.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

LINQ II Insertable Cardiac Monitor

Tool B, the LINQ II, offers enhanced usability through its remote programming capabilities and patient-facing MyCareLink Heartu2122 mobile app for data transmission, which streamlines long-term monitoring for both patients and clinicians. While Tool A provides rapid, automated analysis for clinicians, Tool B's features extend usability to the patient experience and remote management of chronic conditions.

Clinical Value

LINQ II Insertable Cardiac Monitor

While both tools offer significant clinical value in their respective domains, Tool B, the LINQ II, provides long-term, continuous heart rhythm monitoring for up to 4.5 years, coupled with AI-powered accuracy and a pediatric indication. This sustained, comprehensive monitoring for chronic conditions and a broader patient demographic offers a profound and lasting clinical impact compared to Tool A's acute assessment for pulmonary embolism severity.

Pricing & Value

Tie

Both Tool A and Tool B have undisclosed enterprise pricing that requires direct vendor contact, and neither provides public pricing details or free trial options. Without specific pricing information or detailed value-based outcomes data for either product, it is not possible to definitively determine a winner in this dimension.

Enterprise Readiness

LINQ II Insertable Cardiac Monitor

Tool B, from Medtronic, demonstrates superior enterprise readiness due to Medtronic's long-standing global presence, extensive history (founded in 1949), and a proven track record with over 1 million patients having received their ICMs worldwide. While Tool A is also HIPAA and FDA compliant, Medtronic's scale and established customer base indicate a higher level of organizational maturity and proven scalability for large healthcare systems.

Innovation

LINQ II Insertable Cardiac Monitor

Tool B, the LINQ II, showcases broader innovation by combining AI algorithms (AccuRhythmu2122 and innovative PVC detection) for enhanced accuracy in arrhythmia diagnosis with long-term continuous monitoring (up to 4.5 years), remote programming, and a comprehensive mobile app for patient engagement. While Tool A innovates in rapid, automated image analysis for acute conditions, Tool B's integrated approach to chronic disease management, including remote capabilities and extended monitoring, represents a more multifaceted innovative solution.

Support & Docs

Tie

The provided structured facts do not contain specific information regarding the availability or quality of support and documentation for either Tool A or Tool B. Without this crucial information, it is not possible to differentiate between the two products on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Rapid RV/LV	LINQ II Insertable Cardiac Monitor
Name	Rapid RV/LV	LINQ II Insertable Cardiac Monitor
Company	RapidAI (formerly iSchemaView)	Medtronic
Tagline	AI-powered rapid assessment of pulmonary embolism severity.	Advanced insertable cardiac monitoring with AI-powered accuracy and remote management.
Primary Function/Key Use Case	Rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans.	Long-term, continuous heart rhythm monitoring with remote programming and enhanced accuracy for diagnosing arrhythmias.
Specialties	Cardiology, Pulmonology, Radiology	Cardiology
Specific AI Algorithms/Features	AI-powered analysis of CTPA images, Automated measurement of right and left ventricle diameters, Calculation of RV/LV ratio, Annotated images showing ventricular measurements.	AccuRhythmu2122 AI algorithms for enhanced accuracy, Innovative PVC detection algorithm.

Videos

Demos, reviews, and walkthroughs featuring Rapid RV/LV and LINQ II Insertable Cardiac Monitor.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How does Rapid RV/LV integrate into the existing CTPA interpretation workflow for pulmonary embolism, and what is the expected time-to-value for clinicians in acute patient management?

Rapid RV/LV automatically analyzes CTPA images to provide RV/LV ratios within minutes, directly integrating into the radiology reading workflow to support rapid assessment of PE severity. This rapid analysis aims to provide immediate actionable insights, accelerating clinical decision-making for acute PE patients.

What specific clinical advantages do the LINQ II's AccuRhythm AI algorithms offer in terms of diagnostic accuracy for arrhythmias, and in which patient populations is this most impactful?

The LINQ II's AccuRhythm AI algorithms enhance the accuracy of arrhythmia detection, including an innovative PVC detection algorithm, which helps reduce false positives and identify clinically significant events. This is particularly impactful for patients with unexplained syncope, palpitations, or cryptogenic stroke where elusive arrhythmias are suspected.

What is the depth of EHR integration for each tool, and what audit-trail features are available to track AI-generated insights or device data within the patient record?

Rapid RV/LV integrates with the broader Rapid PE solution and can push annotated images and measurements to PACS and potentially EHRs, providing a clear record of the AI analysis for auditability. The LINQ II transmits continuous monitoring data via MyCareLink, which can be integrated into cardiology EMRs, offering a comprehensive patient record and an audit trail of detected arrhythmias and device interactions.

Considering Rapid RV/LV's utility across Cardiology, Pulmonology, and Radiology, how does it facilitate a consistent approach to PE severity assessment across these specialties, especially for multi-site hospital systems?

Rapid RV/LV provides standardized, automated RV/LV ratio measurements, ensuring consistent assessment of PE severity across multiple specialties involved in patient care. For multi-site systems, its on-premises or hybrid deployment model allows for centralized management of the AI solution, facilitating uniform adoption and data sharing across different sites.

What is the typical learning curve for clinicians and support staff in utilizing each tool effectively, and what level of ongoing support and training can be expected from the vendors?

For Rapid RV/LV, the automated analysis suggests a minimal learning curve for reviewing results, with vendor support likely focused on integration and system maintenance. For LINQ II, Medtronic provides comprehensive training and ongoing support for effective patient management and data interpretation, including resources for device insertion and follow-up on the CareLink Network.

Are customer references or case studies available to demonstrate the real-world impact and clinical benefits of each tool, and how do these inform patient selection?

RapidAI, as a prominent AI imaging company, has received FDA clearance for Rapid RV/LV and has clinical statements on its impact in acute care settings, suggesting availability of customer references or case studies. Medtronic states over 1 million patients have received an ICM worldwide, indicating extensive real-world use and likely availability of clinical evidence and patient stories to guide patient selection for long-term arrhythmia diagnosis.